| 產(chǎn)品編號 | bs-14519R-Gold |
| 英文名稱1 | Rabbit Anti-phospho-eIF2B epsilon (Ser539)/Gold Conjugated antibody |
| 中文名稱 | 膠體金標記的磷酸化eIF2B蛋白抗體 |
| 別 名 | eIF2B epsilon (phospho S539); CACH; CLE; EI2BE_HUMAN; EIF 2B; eIF 2B GDP GTP exchange factor; eIF 2B GDP GTP exchange factor subunit epsilon; eIF-2B GDP-GTP exchange factor subunit epsilon; EIF2B; EIF2B5; EIF2BE; EIF2Bepsilon; Eukaryotic Translation Initiation Factor 2 Beta Epsilon; Eukaryotic Translation Initiation Factor 2 Beta Epsilon; Eukaryotic translation initiation factor 2B subunit 5 epsilon 82kDa; Eukaryotic translation initiation factor 2B subunit 5 epsilon; LVWM; Translation initiation factor eIF 2B subunit epsilon; Translation initiation factor eIF-2B subunit epsilon. |
| 規(guī)格價格 | 100ul/2980元 購買 大包裝/詢價 |
| 說 明 書 | 100ul（10nm 15nm 35nm） |
| 產(chǎn)品類型 | 磷酸化抗體 |
| 研究領域 | 細胞生物 神經(jīng)生物學 信號轉(zhuǎn)導 表觀遺傳學 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應 | Human, |
| 產(chǎn)品應用 | IEM=1:20-200 ICA=1:20-200 ChIP=1:20-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 80kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 0.4mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human EFHC1 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲 存 液 | 0.02M TBS(pH8.2) with 1% BSA, 0.03% Proclin300. |
| 保存條件 | Store at 2-8 oC for 3-6 months. Avoid repeated freeze/thaw cycles. |
| 產(chǎn)品介紹 |
background: This gene encodes one of five subunits of eukaryotic translation initiation factor 2B (EIF2B), a GTP exchange factor for eukaryotic initiation factor 2 and an essential regulator for protein synthesis. Mutations in this gene and the genes encoding other EIF2B subunits have been associated with leukoencephalopathy with vanishing white matter. [provided by RefSeq, Nov 2009] Function: Catalyzes the exchange of eukaryotic initiation factor 2-bound GDP for GTP. Tissue Specificity: Widely expressed. Not detected in lymphocytes. DISEASE: Defects in EIF2B5 are a cause of leukodystrophy with vanishing white matter (VWM) [MIM:603896]. VWM is a leukodystrophy that occurs mainly in children. Neurological signs include progressive cerebellar ataxia, spasticity, inconstant optic atrophy and relatively preserved mental abilities. The disease is chronic-progressive with, in most individuals, additional episodes of rapid deterioration following febrile infections or minor head trauma. While childhood onset is the most common form of the disorder, some severe forms are apparent at birth. A severe, early-onset form seen among the Cree and Chippewayan populations of Quebec and Manitoba is called Cree leukoencephalopathy. Milder forms may not become evident until adolescence or adulthood. Some females with milder forms of the disease who survive to adolescence exhibit ovarian dysfunction. This variant of the disorder is called ovarioleukodystrophy. Similarity: Belongs to the eIF-2B gamma/epsilon subunits family. Contains 1 W2 domain. Database links: Entrez Gene: 8893 Human Omim: 603945 Human SwissProt: Q13144 Human Unigene: 283551 Human Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關(guān)于肽鏈的設計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
